Clincosm LogoSign in Get a demo

Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadimiR-01)

Sponsor
Xinqiao Hospital of Chongqing (Other)
Overall Status
Unknown status
CT.gov ID
NCT03074175
Collaborator
(none)
240
Enrollment
1
Location
2
Arms
29
Anticipated Duration (Months)
8.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Lung cancer is a malignant tumor that causes the highest morbidity and mortality, and the main pathological type is non-small cell lung cancer (NSCLC). Most of them present with advanced stage at diagnosis. Radiotherapy is an important treatment strategy for advanced non-small cell lung cancer. However patients have different responses to radiotherapy due to individual differences, thus there is still lacking of sensitive markers to predict treatment response at present. Using bioinformatics to process the data and small sample clinical trial, our previous study found 5 plasma miRNAs were related to radiosensitivity. The design is controlled clinical trial. According to the size of lung lesions, the investigators divided the patients into hyperfractionated radiotherapy group（50Gy/11F/2W) with lesion ≤5cm in diameter and conventional fractionated radiotherapy group（60Gy/30F/6W）with lesion >5cm in diameter.

Condition or Disease Intervention/Treatment Phase
  • Radiation: radiotherapy
 N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
240 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.
Anticipated Study Start Date :
Jul 1, 2017
Anticipated Primary Completion Date :
Aug 1, 2019
Anticipated Study Completion Date :
Dec 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: hyperfractionated radiotherapy group

According to the size of lung lesions,we divided the patients with lesion ≤5cm in diameterand into hyperfractionated radiotherapy group（50Gy/11F/2W).

Radiation: radiotherapy
The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 <25%, lung V30 <18%, spinal cord <36 Gy.
Experimental: conventional fractionated radiotherapy group

According to the size of lung lesions,we divided the patients with lesion >5cm in diameterand into conventional fractionated radiotherapy group（60Gy/30F/6W）.

Radiation: radiotherapy
The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 <25%, lung V30 <18%, spinal cord <36 Gy.

Outcome Measures

Primary Outcome Measures

  1. Objective Response Rate（ORR） [up to two and a half years]

    Based on the WHO evaluation criteria for the therapeutic effect of solid tumors, the evaluation of the therapeutic effect was divided into complete remission (CR),partial remission (PR), no change (NC) and progression of disease (PD). The CR + PR meant objective response rate (ORR).

Secondary Outcome Measures

  1. Correlation between the expression level of miRNAs and the ORR. [up to two and a half years]

    Plasma samples were collected in patients with NSCLC before radiotherapy. qRT- PCR was used to detect miRNAs expression in these plasma samples. The correlation between expression of miRNAs and radiotherapy in patients was analyzed and the value of best cut-off miRNA was calculated though receiver operating characteristic (ROC).

  2. Progression free survival（PFS） [up to two and a half years]

    According to the follow-up data, whether there is difference in progression free survival (PFS) between miRNAs high expression and miRNAs low expression.

  3. side effects of radiation [up to two and a half years]

    According to the follow-up data, whether there is difference in side effects of radiation between hyperfractionated radiotherapy group and conventional fractionated radiotherapy group.

  4. quality of life [up to two and a half years]

    According to the follow-up data, whether there is difference in quality of life between hyperfractionated radiotherapy group and conventional fractionated radiotherapy group.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Pathological histology and/or cytology confirmed NSCLC;

  2. Based on AJCC Cancer Staging, IIIA, IIIB, IV lung cancer patients with NSCLC;

  3. PS 0-2;

  4. Expected survival > 3 months;

  5. Age 18~75 years old;

  6. The function of lung, liver, kidney, bone marrow was normal;

  7. The patients had not received radiotherapy for previous primary tumor and metastases;

  8. At least accept 2-4 cycles of chemotherapy,not disease progression after chemotherapy,start radiotherapy in two weeks after the last cycle of chemotherapy;

  9. Wild-type EGFR;

  10. Sensitive mutant EGFR, but refused to targeted therapy;

  11. In line with the indications of radiotherapy and accept it;

  12. Voluntarily enrolled to participate in,better compliance, cooperate with experimental observations, and sign informed consent.

Exclusion Criteria:

  1. Vital organs (e.g., heart, liver, kidney) have serious dysfunction;

  2. Patients with other malignancies;

  3. Patients with a history of autoimmune disease;

  4. The patients are pregnant and lactating (Women of childbearing age need to check the pregnancy test);

  5. In the activity of acute or chronic infectious diseases;

  6. Patients with a clear history of drug allergy or allergic genus;

  7. Patients with participating in other clinical trials at the same time;

  8. Other cases that researchers believe that patients should not participate in the present trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Xinqiao Hospital of Chongqing Chongqing China 400000

Sponsors and Collaborators

  • Xinqiao Hospital of Chongqing

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jianguo Sun, Deputy director, Xinqiao Hospital of Chongqing
ClinicalTrials.gov Identifier:
NCT03074175
Other Study ID Numbers:
  • XQonc-005
First Posted:
Mar 8, 2017
Last Update Posted:
Mar 8, 2017
Last Verified:
Mar 1, 2017
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung

Study Results

No Results Posted as of Mar 8, 2017